SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
Authors:
Open Access
- 1 November 2020
- journal article
- review article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 14, 4775-4788
Abstract
Diabetic cardiomyopathy (DCM) characterized by diastolic and systolic dysfunction independently of hypertension and coronary heart disease, eventually develops into heart failure, which is strongly linked to a high prevalence of mortality in people with diabetes mellitus (DM). Sodium–glucose cotransporter type2 inhibitors (SGLT2Is) are a novel type of hypoglycemic agent in increasing urinary glucose and sodium excretion. Excitingly, the EMPA-REG clinical trial proved that empagliflozin significantly reduced the relative risk of cardiovascular (CV) death and hospitalization for heart failure (HHF) in patients with type 2 DM (T2DM) plus CV disease (CVD). The EMPRISE trial showed that empagliflozin decreased the risk of HHF in T2DM patients with and without a CVD history in routine care. These beneficial effects of SGLT2Is could not be entirely attributed to glucose-lowering or natriuretic action. There could be potential direct mechanisms of SGLT2Is in cardioprotection. Recent studies have shown the effects of SGLT2Is on cardiac iron homeostasis, mitochondrial function, anti-inflammation, anti-fibrosis, antioxidative stress, and renin–angiotensin–aldosterone system activity, as well as GlcNAcylation in the heart. This article reviews the current literature on the effects of SGLT2Is on DCM in preclinical studies. Possible molecular mechanisms regarding potential benefits of SGLT2Is for DCM are highlighted, with the purpose of providing a novel strategy for preventing DCM.Keywords
This publication has 139 references indexed in Scilit:
- Pathological Role of Serum- and Glucocorticoid-Regulated Kinase 1 in Adverse Ventricular RemodelingCirculation, 2012
- Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapyNature Reviews Cardiology, 2012
- Insulin Resistance and Heart FailureHeart Failure Clinics, 2012
- Mitochondrial dysfunction in diabetic cardiomyopathyBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Biology of Human Sodium Glucose TransportersPhysiological Reviews, 2011
- SGLT2 Mediates Glucose Reabsorption in the Early Proximal TubuleJournal of the American Society of Nephrology, 2011
- Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family membersDiabetes Therapy, 2010
- Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathyGlycobiology, 2010
- Enhanced expressions of sodium–glucose cotransporters in the kidneys of diabetic Zucker ratsDiabetes Research and Clinical Practice, 2009
- Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: The Cardiovascular Health StudyAmerican Heart Journal, 1997